Evaluation of CA 125, BUN, and Creatinine Serum in Ovarian Cancer Patients Receiving Paclitaxel-Cisplatin Chemotherapy Treatment

Rini Noviyani, P. A. Indrayathi, I. N. G. Budiana, Rasmaya Niruri, K. Tunas, Tamara Candra Paramitha

2018

Abstract

The effectiveness and side effects of paclitaxel-cisplatin chemotherapy were assessed from the patient’s treatment progress and toxicity level. The objective was to evaluate these two criteria through the assessment of CA 125, BUN, and creatinine serum in patients as an approach to overcome the data limitation at Sanglah General Hospital. Observational retrospective research with patients who had epithelial ovarian cancer (EOC) at Stages I, II, III, and IV was conducted from February-March 2018. Patients’ blood samples were checked before the first and after the sixth cycle of chemotherapy. The data were processed with the Shapiro-Wilks normality test. As for the abnormally distributed data, they were analyzed statistically using the Wilcoxon test in SPSS. The mean values of CA 125 before the first and after the sixth chemotherapy cycles were 9,429.6 ± 1,5978.7 U/ml and 31.65 ± 36.07 U/ml, respectively (p-value= 0109). The mean values of BUN parameter were 10.63 ± 2.95 mg/dl and 14.83 ± 7.176 mg/dl (p-value= 0.315), respectively. The creatinine serums were averagely 0.693 ± 0.0929 mg/dl and 0.78 ± 0.2053 mg/dl (p-value= 0.417), respectively. There were differences in the levels of CA 125, BUN, and creatinine serum before the first and after the sixth cycles.

Paper Citation

in Harvard Style

Noviyani R., Indrayathi P., Budiana I., Niruri R., Tunas K. and Paramitha T. (2018). Evaluation of CA 125, BUN, and Creatinine Serum in Ovarian Cancer Patients Receiving Paclitaxel-Cisplatin Chemotherapy Treatment.In Proceedings of the 1st Muhammadiyah International Conference on Health and Pharmaceutical Development - Volume 1: MICH-PhD, ISBN 978-989-758-349-0, pages 33-38. DOI: 10.5220/0008238900330038

in Harvard Style

Noviyani R., Indrayathi P., Budiana I., Niruri R., Tunas K. and Paramitha T. (2018). Evaluation of CA 125, BUN, and Creatinine Serum in Ovarian Cancer Patients Receiving Paclitaxel-Cisplatin Chemotherapy Treatment.In Proceedings of the 1st Muhammadiyah International Conference on Health and Pharmaceutical Development - Volume 1: MICH-PhD, ISBN 978-989-758-349-0, pages 33-38. DOI: 10.5220/0008238900330038

in Bibtex Style

@conference{mich-phd18,
author={Rini Noviyani and P. A. Indrayathi and I. N. G. Budiana and Rasmaya Niruri and K. Tunas and Tamara Candra Paramitha},
title={Evaluation of CA 125, BUN, and Creatinine Serum in Ovarian Cancer Patients Receiving Paclitaxel-Cisplatin Chemotherapy Treatment},
booktitle={Proceedings of the 1st Muhammadiyah International Conference on Health and Pharmaceutical Development - Volume 1: MICH-PhD,},
year={2018},
pages={33-38},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0008238900330038},
isbn={978-989-758-349-0},
}

in Bibtex Style

@conference{mich-phd18,
author={Rini Noviyani and P. A. Indrayathi and I. N. G. Budiana and Rasmaya Niruri and K. Tunas and Tamara Candra Paramitha},
title={Evaluation of CA 125, BUN, and Creatinine Serum in Ovarian Cancer Patients Receiving Paclitaxel-Cisplatin Chemotherapy Treatment},
booktitle={Proceedings of the 1st Muhammadiyah International Conference on Health and Pharmaceutical Development - Volume 1: MICH-PhD,},
year={2018},
pages={33-38},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0008238900330038},
isbn={978-989-758-349-0},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 1st Muhammadiyah International Conference on Health and Pharmaceutical Development - Volume 1: MICH-PhD,
TI - Evaluation of CA 125, BUN, and Creatinine Serum in Ovarian Cancer Patients Receiving Paclitaxel-Cisplatin Chemotherapy Treatment
SN - 978-989-758-349-0
AU - Noviyani R.
AU - Indrayathi P.
AU - Budiana I.
AU - Niruri R.
AU - Tunas K.
AU - Paramitha T.
PY - 2018
SP - 33
EP - 38
DO - 10.5220/0008238900330038

in EndNote Style

TY - CONF

JO - Proceedings of the 1st Muhammadiyah International Conference on Health and Pharmaceutical Development - Volume 1: MICH-PhD,
TI - Evaluation of CA 125, BUN, and Creatinine Serum in Ovarian Cancer Patients Receiving Paclitaxel-Cisplatin Chemotherapy Treatment
SN - 978-989-758-349-0
AU - Noviyani R.
AU - Indrayathi P.
AU - Budiana I.
AU - Niruri R.
AU - Tunas K.
AU - Paramitha T.
PY - 2018
SP - 33
EP - 38
DO - 10.5220/0008238900330038